BACKGROUND: The role of T-cell responses against Mycobacterium tuberculosis antigens in tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is unclear. METHODS: Peripheral blood mononuclear cells from 45 HIV patients with treated TB, of whom 12 developed TB-IRIS, were collected at weeks 0, 2, and 6 of antiretroviral therapy (ART). Production of interferon-gamma (IFN-γ) and interleukin-2 by T cells after stimulation with purified protein derivative (PPD) or early secretory antigenic target-6 (ESAT-6) and T-cell expressions of CCR5 and CXCR3 were assessed by flow cytometry. IFN-γ and CXCL10 were assayed by enzyme-linked immunosorbent assay. RESULTS: TB-IRIS patients had higher proportions of PPD- and ESAT-6-reactive IFN-γ⁺CD4⁺ and CD3⁺CD4⁻ T cells at weeks 0, 2, and 6. IFN-γ levels were also higher in peripheral blood mononuclear cell culture supernatants at all times with PPD but only at weeks 2 and 6 with ESAT-6. There were few differences for interleukin-2. CXCL10 levels in supernatants after PPD and ESAT-6 stimulation were only higher at week 6. CXCR3⁺/CCR5⁺CD4⁺ T cells were higher at week 2, and CCR5⁺CD4⁺ T cells were higher at week 6. CONCLUSIONS: TB-IRIS is associated with Th1 responses against M. tuberculosis antigens by CD4⁺ and CD3⁺CD4⁻ T cells that are present before ART and amplified afterward. It is unclear if these cause immunopathology or reflect a high pathogen load.
BACKGROUND: The role of T-cell responses against Mycobacterium tuberculosis antigens in tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is unclear. METHODS: Peripheral blood mononuclear cells from 45 HIVpatients with treated TB, of whom 12 developed TB-IRIS, were collected at weeks 0, 2, and 6 of antiretroviral therapy (ART). Production of interferon-gamma (IFN-γ) and interleukin-2 by T cells after stimulation with purified protein derivative (PPD) or early secretory antigenic target-6 (ESAT-6) and T-cell expressions of CCR5 and CXCR3 were assessed by flow cytometry. IFN-γ and CXCL10 were assayed by enzyme-linked immunosorbent assay. RESULTS:TB-IRIS patients had higher proportions of PPD- and ESAT-6-reactive IFN-γ⁺CD4⁺ and CD3⁺CD4⁻ T cells at weeks 0, 2, and 6. IFN-γ levels were also higher in peripheral blood mononuclear cell culture supernatants at all times with PPD but only at weeks 2 and 6 with ESAT-6. There were few differences for interleukin-2. CXCL10 levels in supernatants after PPD and ESAT-6 stimulation were only higher at week 6. CXCR3⁺/CCR5⁺CD4⁺ T cells were higher at week 2, and CCR5⁺CD4⁺ T cells were higher at week 6. CONCLUSIONS:TB-IRIS is associated with Th1 responses against M. tuberculosis antigens by CD4⁺ and CD3⁺CD4⁻ T cells that are present before ART and amplified afterward. It is unclear if these cause immunopathology or reflect a high pathogen load.
Authors: Joseph R Maxwell; Rajwardhan Yadav; Robert J Rossi; Carl E Ruby; Andrew D Weinberg; Hector L Aguila; Anthony T Vella Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Benjamin G Oliver; Julian H Elliott; Patricia Price; Michael Phillips; David A Cooper; Martyn A French Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Daniel L Barber; Katrin D Mayer-Barber; Lis R V Antonelli; Mark S Wilson; Sandra White; Patricia Caspar; Sara Hieny; Irini Sereti; Alan Sher Journal: Blood Date: 2010-07-23 Impact factor: 22.113
Authors: Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: Graeme Meintjes; Katalin Andrea Wilkinson; Molebogeng Xheeda Rangaka; Keira Skolimowska; Kerryn van Veen; Musaed Abrahams; Ronnett Seldon; Dominique J Pepper; Kevin Rebe; Priscilla Mouton; Gilles van Cutsem; Mark Patrick Nicol; Gary Maartens; Robert John Wilkinson Journal: Am J Respir Crit Care Med Date: 2008-08-28 Impact factor: 21.405
Authors: Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson Journal: Lancet Infect Dis Date: 2015-02-09 Impact factor: 25.071
Authors: Laura W Musselwhite; Bruno B Andrade; Susan S Ellenberg; Ann Tierney; Pablo F Belaunzaran-Zamudio; Adam Rupert; Michael M Lederman; Ian Sanne; Juan G Sierra Madero; Irini Sereti Journal: EBioMedicine Date: 2016-01-14 Impact factor: 8.143
Authors: Tatiana Pereira da Silva; Carmem Beatriz Wagner Giacoia-Gripp; Carolina A Schmaltz; Flavia Marinho Sant'Anna; Maria Helena Saad; Juliana Arruda de Matos; Julio Castro Alves de Lima E Silva; Valeria Cavalcanti Rolla; Mariza Gonçalves Morgado Journal: BMC Infect Dis Date: 2017-09-06 Impact factor: 3.090